Daratumumab to Treat Active Lupus Nephritis | NCT04868838

NCT04868838

Protocol Section

Identification Module

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Status Module

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Daratumumab	Experimental	Subjects diagnosed with lupus nephritis will receive Daratumumab once weekly for 8 weeks and then once every 2 weeks for 8 additional does (+/- 4 days). Subjects will be followed for a total of 24 months (18 months after the last daratumumab administration).	Drug: Daratumumab

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Daratumumab	Drug	1800 mg administered by subcutaneous injection by manual push over approximately 3-5 minutes in the abdominal subcutaneous tissues in the left/right locations, alternating between individual doses.

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Efficacy of daratumumab in inducing complete(CR) or partial(PR) renal remission in patients with active class III or IV Lupus Nephritis	Complete Renal Response:- < 500 mg proteinuria/24 hours, Inactive urinary sediment (<10 RBC/HPF and absence of RBC casts), No greater than a 15% reduction in eGFR from enrollment	12 months after first infusion of Daratumumab
Efficacy of daratumumab in inducing complete(CR) or partial(PR)	Partial Renal Response: > 50% reduction in 24-hour proteinuria and proteinuria < 1g/24hr if baseline 24hr proteinuria, - ≤3 g/24hr and proteinuria ≤ 3 g/24hr if starting proteinuria > 3 g/24hrs. , Improved urinary sediment (>=50% reduction in RBC/HPF and absence of RBC casts), No greater than a 20% reduction in baseline eGFR	12 months after first infusion of Daratumumab

Secondary Outcomes

Measure	Description	Time Frame
Safety of daratumumab in patients with active class III/IV LN.	Incidence of major infections defined in the development of pneumonia, grade 3 urinary tract infection/pyelonephritis, sepsis, meningitis or anemia.	24 months after first infusion of Daratumumab
Improvement from proteinuria

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Age ≥ 18 years of age.
Diagnosis of SLE according to current American College of Rheumatology (ACR) criteria.
Renal biopsy confirming the diagnosis of active class III/IV (± class V) LN (based on International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003) within 12 months of enrollment.
Proteinuria ≥ 500 mg over 24 hours.
eGFR ≥ 30 ml/min/SA.
Subjects should be able to give informed consent.

Exclusion Criteria:

Pregnancy.
Hepatitis B or C, HIV
Anemia with Hgb < 8.0 g/dL.
Thrombocytopenia with platelet count < 100'000.
Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complication.
Unable to provide consent.
Patients receiving > 10 mg of oral prednisone or glucocorticoid equivalent if on corticosteroids for > 2 weeks (patients would be allowed to be on > 10 mg of prednisone or its oral equivalent as long as the duration is ≤ 2 weeks).
Patients who had received immunosuppressive therapy including cyclosporine, tacrolimus or azathioprine in the last 3 months.
Patients who have received cyclophosphamide in the last 6 months.
Patients who received rituximab previously with CD20 count of zero at the time of enrollment.
Patient are allowed to be on MMF at time of enrollment but no higher than total of 1500mg/day.
For women who are not postmenopausal (≥ 12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to remain abstinent or use two adequate methods of contraception, including at least one method with a failure rate of less than (<) 1 percent (%) per year, during the treatment period and for at least 12 months after the last dose of study drug.
For men: agreement to remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for at least 12 months after the last dose of study drug and agreement to refrain from donating sperm during this same period.
Patients with diagnosis of glaucoma.

ID	Term
D005921	Glomerulonephritis
D009393	Nephritis
D007674	Kidney Diseases
D014570	Urologic Diseases